Alphabet’s GV leads funding in gene editing company Verve Therapeutics

Published 5y ago

GV, Alphabet Inc’s venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases. Gene editing therapies are seen to have huge scope in treatin... More »